ICCM יחס שווי שוק לנכסים נקיים IceCure Medical
The price trajectory of IceCure Medical Ltd (ICCM) shown below demonstrates the dynamics of an asset whose success relies on the recognition of its tumor freezing method, with system costs currently at 0.30. The business develops equipment for the bloodless removal of kidney and breast tumors, targeting the B2B segment. IceCure Medical Ltd (ICCM) is displacing competitors in the minimally invasive intervention space by offering clinics undeniable medical advantages.
ICCM (IceCure Medical Ltd): פילוחים אנליטיים ודוחות לפי אינדיקטורים
Steady demand for cryoablation disposable probes directly impacts the P/BV ratio of IceCure Medical Ltd (ICCM). This ratio compares the business's market value to its net book value. The metric determines the premium investors are willing to pay for every dollar of equity. A high figure reflects market expectations regarding the profitability of the "razor-and-blade" model. A decline in this indicator may signal an undervaluation of the tangible assets of IceCure Medical Ltd (ICCM).